Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 26

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 26
---
 entirety for a description of the assumptions made, and the qualifications and limitations upon the review undertaken by Leerink Partners in preparing its opinion. The Agreement In accordance with the Agreement, each of the Company and the Purchaser has agreed to certain covenants, including covenants relating to the Discontinuance, satisfying the conditions precedent to their respective obligations under the Agreement and the Plan of Arrangement, and obtaining the required Shareholder and court approvals described in the Agreement. A copy of the Plan of Arrangement is attached to this Circular and Proxy Statement asAnnex E. Further, a copy of the Agreement is attached to this Circular and Proxy Statement asAnnex A

9

and is available on the Company’s profile on EDGAR at www.sec.gov and on SEDAR+ at www.sedarplus.ca.We urge you to read the full text of the Agreement andthe Plan of
Arrangement because they are the legal documents that govern the Arrangement.

Conditions to the Arrangement

The obligations of the Parties to complete the Arrangement under the Agreement are subject to the satisfaction or waiver of certain conditions
described further under the heading “The Arrangement Agreement—Conditions Precedent to the Arrangement.”

Termination of Agreement

The Parties may
agree in writing to terminate the Agreement and abandon the Arrangement at any time prior to the Arrangement becoming effective. In addition, the Company or the Purchaser may terminate the Agreement and abandon the Arrangement at any time prior to
the Effective Date if certain specific events occur. Depending on the termination event, a Termination Payment in an amount equal to $2,000,000 may be payable by the Company. See “The Arrangement —Termination Payment and Expenses” in this Circular and Proxy Statement for more information.

CVR Agreement

Under the terms of the Agreement, in addition to the Cash Amount, Shareholders will receive for each Common Share held at the Effective Time a
CVR pursuant to the CVR Agreement, each entitling the holder to receive a pro rata portion of contingent cash payments equal to (i) 100% of certain additional receivables that may be received by the Company within ninety (90) days following
Closing (net of certain permitted deductions incurred in connection therewith); (ii) a percentage of the net proceeds received from the Company’s existing partnerships with Bristol-Myers Squibb, Debiopharm and DCx, as follows: (a) 90% received
from the Closing date until